Plasma endothelin in congestive heart failure: A predictor of cardiac death?

Journal of Cardiac Failure

Volumn 2, Issue 2, 1996, Pages 71-76

  Galatius Jensen, Søren ^a,b   Wroblewski, Henrik ^b   Emmeluth, Claus ^c   Bie, Peter ^c   Haunsø, Stig ^b   Kastrup, Jens ^b  

^a HILLERØD HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Heart disease; Peptides; Prognosis

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; BIOLOGICAL MARKERS; ENDOTHELINS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030160890     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(96)80025-X     Document Type: Article

References (19)

1. Yanagisawa M, Kurihara H, Kimura K, Tomobe Y, Kobayashi M, Mitsuy Y, Goto K, Masaki T: A novel potent vasoconstricting peptide produced by vascular endothelial cells. Nature 1988;332:411-5
2. Hirata Y, Takagi Y, Fukuda Y: Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-8
3. Cody RJ: The potential role of endothelin as a vasoconstrictor substance in congestive heart failure. Eur Heart J 1992;13:1573-8
4. Margulies KB, Hildebrand FLJ, Lerman A, Perrella MA, Burnett JCJ: Increased endothelin in experimental heart failure. Circulation 1990;82:2226-30
5. Lerman A, Kubo SH, Tschumperlin LK, Burnett JCJ: Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992;20:849-53
6. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JCJ: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67: 719-24
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9
8. CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) Trial Study Group: Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35
9. Walsh WF, Greenberg BH: Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 1981;64:499-505
10. Swerdlow CD, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983;308:1436-42
11. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23
12. Creager MA, Faxon DP, Halperin JL, Melidossian CD, McCabe CH, Schick EC, Ryan TJ: Determinants of clinical response and survival in patients with congestive heart failure treated with captopril. Am Heart J 1982;104:1147-54
13. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82: 1730-6
14. Gottlieb SS, Kukin ML, Ahern D, Packer M: Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure [published erratum appears in J Am Coll Cardiol 1989;14:812]. J Am Coll Cardiol 1989;13: 1534-9
15. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RM, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51
16. Terashita Z, Shibouta Y, Imura Y, Iwasaki K, Nishikawa K: Endothelin-induced sudden death and the possible involvement of platelet activating factor (PAF). Life Sci 1989;45: 1911-8
17. Salvati P, Chierchia S, Dho L, Ferrario RG, Parenti P, Vicedomini G, Patrono C: Proarrhythmogenic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol 1991;17:1007-14
18. Erhardt L, Haunsø S, Luonamanmaki K, Van Mieghem D, Ceremuzynsky L, Kristinson A, Blumenthal M, Maclean A, Juul-Møller S: Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1994;15:S341
19. Lee Chia-Sen D, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, Goroll AH, Newell JB, Strauss W, Haber E: Heart failure in outpatients. N Engl J Med 1982;306: 699-705